Exercise of the over-allotment option in the IPO of Devyser Diagnostics AB (publ)’s shares and end of the stabilisation period

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, JAPAN, CANADA, AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE

Stockholm, 7 January, 2022

Carnegie Investment Bank AB (publ) (“Carnegie”) exercises the over-allotment option regarding 610,886 shares in Devyser Diagnostics AB (publ) (“Devyser” or the “Company”). The stabilisation period has now ended and no further stabilisation actions will be conducted.

As announced on 1 December 2021 in connection with the listing of the Company's shares on Nasdaq First North Premier Growth Market (“First North”) and the offering of shares made in connection thereto (the “Offering”), Carnegie has had the opportunity to, as Sole Global Coordinator and Sole Bookrunner, carry out transactions aimed at supporting the market price of the Company’s share at levels above those which might otherwise have prevailed in the open market.

To cover any over-allotments related to the Offering, the Company granted Carnegie an option to issue an additional 625,000 shares, corresponding to approximately 14.6 percent of the total number of shares in the Offering prior to any over-allotments (the “Over-allotment Option”).

Stabilisation transactions have been possible on First North, in the over-the-counter market or otherwise, at any time from the first day of trading in the shares on First North, i.e. 10 December 2021, and for no longer than 30 calendar days thereafter. Carnegie, however, was not required to undertake any stabilisation and there was no assurance that stabilisation would be undertaken. In total, Carnegie has purchased 14,114 shares for the purposes of stabilisation, corresponding to c. 2.3 percent of the Over-allotment Option in total.

As a consequence of Carnegie exercising the Over-allotment Option, the board of directors of Devyser has resolved to issue 610,886 shares at a price corresponding to the issue price in the Offering (SEK 80 per share). The exercise of the Over-allotment Option means that a total of 4,360,886 newly issued shares have been sold in the Offering, corresponding to approximately 27.6 percent of the shares in Devyser after the completion of the Offering. Devyser will thereby be provided with additionally approximately SEK 48,870,880 million, which means that the Company has been provided with approximately SEK 348,870,880 million in total as a result of the Offering, before transaction costs. After the shares in the Over-allotment Option have been registered with the Swedish Companies Registration Office, the total number of outstanding shares in Devyser will amount to 15,798,986.

In connection with the Offering, Carnegie borrowed 625,000 existing shares in the Company from M2 Asset Management AB in order to ensure delivery of all over-allotted shares in the Offering. Due to the exercise of the Over-allotment Option, all borrowed shares will be returned to M2 Asset Management AB.

Carnegie has, in its capacity as stabilisation manager, notified that stabilisation measures have been undertaken, in accordance with article 5(4) in the Market Abuse Regulation 596/2014, on First North as specified below. The contact person at Carnegie is Johan Flintull (tel: +46 8 5886 88 00).

Stabilisation information

Stabilisation transactions

This information is information that Devyser Diagnostics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact persons set out below, at 18:00 CET on 7 January 2022.

For more information, please contact:

Fredrik Alpsten

CEO

Email: fredrik.alpsten@devyser.com

Tel: +46 706 673 106

Sabina Berlin

CFO

Email: sabina.berlin@devyser.com

Tel: +46 739 519 502

About Devyser

Devyser is specialized in the development, manufacture, and sales of diagnostic kits. The products are sold to routine diagnostic laboratories in more than 45 countries. The products are used for complex DNA testing within hereditary diseases, oncology, and transplantation. The products are used to guide targeted cancer therapies, to enable a wide array of genetic tests, as well as in post-transplant follow-up. Devyser’s product development focuses on simplifying and streamlining complex testing processes to improve throughput, reduce hands-on time and produce accurate and trusted results. Devyser was founded in 2004 and is based in Stockholm, Sweden.

Devyser’s shares are listed on Nasdaq First North Premier Growth Market with the short name (ticker) DVYSR. The Company’s certified adviser is Redeye AB, +46 8 121 57 690, certifiedadviser@redeye.se.

Important information

This announcement is not an offer to sell or a solicitation of any offer to buy any securities issued by Devyser Diagnostics AB (publ) (the "Company") in any jurisdiction where such offer or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of such jurisdiction.

Any offering of the securities referred to in this announcement will be made by means of a prospectus. This announcement is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/ EC (and, with respect to the United Kingdom, such regulation as it forms part of the domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018) (the “Prospectus Regulation”). Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus.

In any EEA member state other than Sweden, and in the United Kingdom, this communication is only addressed to and is only directed at qualified investors in that member state or the United Kingdom within the meaning of the Prospectus Regulation (as applicable), for example, only to investors who can receive the offer without an approved prospectus in such EEA member state or in the United Kingdom.

This document and the information contained herein are not for distribution in or into the United States. This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.

In the United Kingdom, this document is only being distributed to and is only directed at (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (ii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i) and (ii) above together being referred to as “relevant persons”). The Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person must not act or rely on this document or any of its contents. Persons distributing this document must satisfy themselves that it is lawful to do so.

Matters discussed in this press release may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “intend”, “estimate”, “will”, “may”, “continue”, “should”, “could” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond the Company’s control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.

The Company does not undertake any obligation to review, update, confirm or release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this communication.